Patients who underwent left atrial appendage closure with a next-generation device were significantly less likely to experience in-hospital major adverse events, including pericardial effusion ...

SOLO-CLOSE demonstrated high success and safety with reduced complexity, offering a promising streamlined option for left ...

A 62-year-old woman was evaluated for recurrent hemorrhagic pericardial effusion. Fourteen years earlier, she had undergone transcatheter closure of an atrial septal defect. A diagnosis was made.

Women who underwent left atrial appendage occlusion for nonvalvular atrial fibrillation experienced more adverse in-hospital outcomes and longer hospital stays compared with men, according to data ...

Women with atrial fibrillation (AF) undergoing left atrial appendage occlusion (LAAO) with the Watchman device (Boston Scientific) have poorer in-hospital outcomes compared with men, according to data ...

(UPDATED) In patients undergoing left atrial appendage (LAA) occlusion, the Amplatzer Amulet device (Abbott) provides better closure as well as noninferior safety and effectiveness compared with the ...

The researchers reported that post-op pericardial effusion was lower in the left pericardiotomy group at 12% versus 21% in the no-intervention group (RR 0.58, 95% CI 0.37-0.91).

Atrial fibrillation (AF) is associated with a 4- to 5-fold increased risk of ischemic stroke and accounts for 25% of the 700,000 cerebrovascular accidents that occur in the United States annually.

The primary endpoint of LAA patent appendage at 45 days by CTTA was 67.6% for Amulet compared to 70% for Watchman/FLX (RR 0.97, 95% CI 0.80-1.16, p=0.713).

The left atrial appendage is a source of atrial natriuretic peptide, and it has been hypothesized that removal of the appendage might impair renal clearance of salt and water, thereby increasing ...